Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicos
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações da UFPB |
Texto Completo: | https://repositorio.ufpb.br/jspui/handle/123456789/16735 |
Resumo: | Dyslipidemias are chronic diseases, characterized by elevation in plasma levels of total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), associated with a decrease in plasma levels of high density lipoprotein (HDL). In part, changes in lipid metabolism are associated with the type of fatty acids ingested in the diet. The high intake of saturated and trans fatty acids contributes to the increase of the plasma levels of LDL, CT, TG and reduction of HDL. In addition, dyslipidemias may favor the development of insulin resistance, systemic arterial hypertension (SAH) and cardiovascular diseases. Studies indicate that probiotics, if consumed in adequate quantities, may play a role in the improvement of disorders in lipid metabolism, reduction of inflammatory markers, attenuation of oxidative stress and reduction of blood pressure. Thus, the general objective of this study was to investigate the effects of supplementation with the Lactobacillus fermentum 296 strain in dyslipidemic rats on cardiometabolic parameters. This was a non-clinical trial performed with male Wistar rats at 90 days of age and divided into three groups: control group (CTL), dyslipidemic (DLP), who received a dyslipidemic diet and placebo solution (PBS), and the group with L. fermentum 296 (DLP + Lf296) with dyslipidemic diet and gavage supplementation with L. fermentum 296 (1.0 x 109 CFU / mL) daily for 4 weeks. At the end of the study, blood was collected for biochemical tests, oral glucose tolerance (OGT) and insulin (TTI) tests were performed, and finally the rats were submitted to surgery for insertion of cannulas into the femoral artery for posterior measurement of the basal blood pressure, obtaining heart rate (HR) records, spectral analysis of systolic blood pressure and pulse interval, baroreflex sensitivity, sympathetic-vagal balance and sympathetic vascular tone in each group. The rats were euthanized and the organs were collected for weighing. Finally, the faeces were collected and the Lactobacillus spp count was performed. The intervention with L. fermentum 296 was able to prevent the increase of total cholesterol levels (111.5 ± 10 vs. 161 ± 18.2 mg / dl), LDL (84.9 ± 10.7 vs. 142.6 ± 20.9 mg / dl), and triglycerides (52.5 ± 4.6 vs. 85 ± 8.3 mg / dl) (p <0.05) in dyslipidemic rats. The administration of L. fermentum 296 prevented increased systolic blood pressure (149.5 ± 3.3 vs. 162.5 ± 1.6 mmHg, p <0.05), and sympathetic cardiovascular tone (-50.8 ± 3.5 vs. -63.4 ± 3.0 mmHg, p < 0.05) in rats fed a dyslipidemic diet. The administration of L. fermentum 296 was not able to prevent insulin resistance (p> 0.05) and damage in cardiac baroreflex control (p> 0.05) caused by the dyslipidemic diet. These results indicate that L. fermentum 296 presents potential for use as a probiotic with the ability to modulate biochemical and cardiovascular parameters of interest for the treatment of cardiometabolic diseases. |
id |
UFPB_a4c586e0b1f7a555a4aeac81bf848f4d |
---|---|
oai_identifier_str |
oai:repositorio.ufpb.br:123456789/16735 |
network_acronym_str |
UFPB |
network_name_str |
Biblioteca Digital de Teses e Dissertações da UFPB |
repository_id_str |
|
spelling |
Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicosDislipidemiaHipertensãoLactobacillusMicrobiotaProbióticosDyslipidemiaHypertensionLactobacillusMicrobiotaProbioticsNutriçãoDieta dislipidêmica - Benefícios à saúdeCNPQ::CIENCIAS DA SAUDE::NUTRICAODyslipidemias are chronic diseases, characterized by elevation in plasma levels of total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), associated with a decrease in plasma levels of high density lipoprotein (HDL). In part, changes in lipid metabolism are associated with the type of fatty acids ingested in the diet. The high intake of saturated and trans fatty acids contributes to the increase of the plasma levels of LDL, CT, TG and reduction of HDL. In addition, dyslipidemias may favor the development of insulin resistance, systemic arterial hypertension (SAH) and cardiovascular diseases. Studies indicate that probiotics, if consumed in adequate quantities, may play a role in the improvement of disorders in lipid metabolism, reduction of inflammatory markers, attenuation of oxidative stress and reduction of blood pressure. Thus, the general objective of this study was to investigate the effects of supplementation with the Lactobacillus fermentum 296 strain in dyslipidemic rats on cardiometabolic parameters. This was a non-clinical trial performed with male Wistar rats at 90 days of age and divided into three groups: control group (CTL), dyslipidemic (DLP), who received a dyslipidemic diet and placebo solution (PBS), and the group with L. fermentum 296 (DLP + Lf296) with dyslipidemic diet and gavage supplementation with L. fermentum 296 (1.0 x 109 CFU / mL) daily for 4 weeks. At the end of the study, blood was collected for biochemical tests, oral glucose tolerance (OGT) and insulin (TTI) tests were performed, and finally the rats were submitted to surgery for insertion of cannulas into the femoral artery for posterior measurement of the basal blood pressure, obtaining heart rate (HR) records, spectral analysis of systolic blood pressure and pulse interval, baroreflex sensitivity, sympathetic-vagal balance and sympathetic vascular tone in each group. The rats were euthanized and the organs were collected for weighing. Finally, the faeces were collected and the Lactobacillus spp count was performed. The intervention with L. fermentum 296 was able to prevent the increase of total cholesterol levels (111.5 ± 10 vs. 161 ± 18.2 mg / dl), LDL (84.9 ± 10.7 vs. 142.6 ± 20.9 mg / dl), and triglycerides (52.5 ± 4.6 vs. 85 ± 8.3 mg / dl) (p <0.05) in dyslipidemic rats. The administration of L. fermentum 296 prevented increased systolic blood pressure (149.5 ± 3.3 vs. 162.5 ± 1.6 mmHg, p <0.05), and sympathetic cardiovascular tone (-50.8 ± 3.5 vs. -63.4 ± 3.0 mmHg, p < 0.05) in rats fed a dyslipidemic diet. The administration of L. fermentum 296 was not able to prevent insulin resistance (p> 0.05) and damage in cardiac baroreflex control (p> 0.05) caused by the dyslipidemic diet. These results indicate that L. fermentum 296 presents potential for use as a probiotic with the ability to modulate biochemical and cardiovascular parameters of interest for the treatment of cardiometabolic diseases.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESAs dislipidemias são doenças crônicas, caracterizadas por elevação nos níveis plasmáticos de colesterol total (CT), triglicerídeos (TG), lipoproteína de baixa densidade (LDL), associada com diminuição nos níveis plasmáticos de lipoproteína de alta densidade (HDL). Em parte, as alterações no metabolismo dos lipídios estão associadas ao tipo de ácidos graxos ingeridos na dieta. O consumo elevado de ácidos graxos saturados e trans contribui para o aumento dos níveis plasmáticos de LDL, CT, TG e redução de HDL. Adicionalmente, as dislipidemias podem favorecer o desenvolvimento de resistência à insulina, hipertensão arterial sistêmica (HAS) e doenças cardiovasculares. Estudos apontam que os probióticos, se consumidos em quantidades adequadas, podem desempenhar um papel importante na melhoria de distúrbios no metabolismo lipídico, na redução de marcadores inflamatórios, na atenuação do estresse oxidativo e na redução da pressão arterial. Sendo assim, o objetivo geral deste estudo foi investigar os efeitos da suplementação com a cepa de Lactobacillus fermentum 296 em ratos dislipidêmicos sobre os parâmetros cardiometabólicos. Trata-se de um ensaio não clínico realizado com ratos Wistar machos com ±90 dias de idade que foram divididos em três grupos: grupo controle (CTL), dislipidêmico (DLP) que recebeu dieta dislipidêmica e solução placebo (PBS), e o grupo dislipidêmico tratado com L. fermentum 296 (DLP + Lf296) com dieta dislipidêmica e suplementação por gavagem com L. fermentum 296 (1,0 x 109 UFC/mL) diariamente por 4 semanas. No final do estudo, o sangue foi coletado para testes bioquímicos, foram realizados testes de tolerância à glicose oral (TOTG) e insulina (TTI) e, finalmente, os ratos foram submetidos à cirurgia para inserção de cânulas na artéria femoral para posterior aferição da pressão arterial basal, obtenção de registros da frequência cardíaca (FC), análise espectral da pressão arterial sistólica e intervalo de pulso, sensibilidade barorreflexa, equilíbrio simpático-vagal e tônus vascular simpático em cada grupo. Os ratos foram eutanasiados e os órgãos foram coletados para pesagem. Finalmente, as fezes foram coletadas e a contagem de Lactobacillus spp foi realizada. A intervenção com L. fermentum 296 foi capaz de prevenir o aumento dos níveis de colesterol total (111,5± 10,0 vs. 161±18,2 mg/dL), LDL (84,9± 10,7 vs. 142,6±20,9 mg/dL) e triglicerídeos (52,5 ± 4,6 vs. 85±8,3 mg/dL) (p <0,05) nos ratos dislipidêmicos. A administração de L. fermentum 296 preveniu o aumento de pressão arterial sistólica (149,5 ± 3,3 vs. 162,5 ± 1,6 mmHg, p<0.05), e do tônus cardiovascular simpático (50,8 ± 3,5 vs. -63,4 ± 3,0 mmHg, p<0.05) em ratos alimentados com dieta dislipidêmica. A administração de L. fermentum 296 não foi capaz de prevenir a resistência à insulina (p>0.05) e o dano no controle baroreflexo cardíaco (p>0.05) causado pela dieta dislipidêmica. Estes resultados indicam que L. fermentum 296 apresenta potencial para uso como probiótico com habilidades de modular parâmetros bioquímicos e cardiovasculares de interesse para o tratamento de doenças cardiometabólicas.Universidade Federal da ParaíbaBrasilCiências da NutriçãoPrograma de Pós-Graduação em Ciências da NutriçãoUFPBAlves, José Luiz de Britohttp://lattes.cnpq.br/6771368391025310Cavalcante, Raissa Georgianna Silva2020-01-13T14:27:01Z2019-04-182020-01-13T14:27:01Z2018-03-21info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttps://repositorio.ufpb.br/jspui/handle/123456789/16735porAttribution-NoDerivs 3.0 Brazilhttp://creativecommons.org/licenses/by-nd/3.0/br/info:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFPBinstname:Universidade Federal da Paraíba (UFPB)instacron:UFPB2020-01-14T06:08:01Zoai:repositorio.ufpb.br:123456789/16735Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufpb.br/PUBhttp://tede.biblioteca.ufpb.br:8080/oai/requestdiretoria@ufpb.br|| diretoria@ufpb.bropendoar:2020-01-14T06:08:01Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB)false |
dc.title.none.fl_str_mv |
Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicos |
title |
Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicos |
spellingShingle |
Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicos Cavalcante, Raissa Georgianna Silva Dislipidemia Hipertensão Lactobacillus Microbiota Probióticos Dyslipidemia Hypertension Lactobacillus Microbiota Probiotics Nutrição Dieta dislipidêmica - Benefícios à saúde CNPQ::CIENCIAS DA SAUDE::NUTRICAO |
title_short |
Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicos |
title_full |
Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicos |
title_fullStr |
Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicos |
title_full_unstemmed |
Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicos |
title_sort |
Administração oral de Lactobacillus fermentum 296 reduz a pressão arterial via inibição do tônus simpático e melhora os parâmetros metabólicos em ratos dislipidêmicos |
author |
Cavalcante, Raissa Georgianna Silva |
author_facet |
Cavalcante, Raissa Georgianna Silva |
author_role |
author |
dc.contributor.none.fl_str_mv |
Alves, José Luiz de Brito http://lattes.cnpq.br/6771368391025310 |
dc.contributor.author.fl_str_mv |
Cavalcante, Raissa Georgianna Silva |
dc.subject.por.fl_str_mv |
Dislipidemia Hipertensão Lactobacillus Microbiota Probióticos Dyslipidemia Hypertension Lactobacillus Microbiota Probiotics Nutrição Dieta dislipidêmica - Benefícios à saúde CNPQ::CIENCIAS DA SAUDE::NUTRICAO |
topic |
Dislipidemia Hipertensão Lactobacillus Microbiota Probióticos Dyslipidemia Hypertension Lactobacillus Microbiota Probiotics Nutrição Dieta dislipidêmica - Benefícios à saúde CNPQ::CIENCIAS DA SAUDE::NUTRICAO |
description |
Dyslipidemias are chronic diseases, characterized by elevation in plasma levels of total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), associated with a decrease in plasma levels of high density lipoprotein (HDL). In part, changes in lipid metabolism are associated with the type of fatty acids ingested in the diet. The high intake of saturated and trans fatty acids contributes to the increase of the plasma levels of LDL, CT, TG and reduction of HDL. In addition, dyslipidemias may favor the development of insulin resistance, systemic arterial hypertension (SAH) and cardiovascular diseases. Studies indicate that probiotics, if consumed in adequate quantities, may play a role in the improvement of disorders in lipid metabolism, reduction of inflammatory markers, attenuation of oxidative stress and reduction of blood pressure. Thus, the general objective of this study was to investigate the effects of supplementation with the Lactobacillus fermentum 296 strain in dyslipidemic rats on cardiometabolic parameters. This was a non-clinical trial performed with male Wistar rats at 90 days of age and divided into three groups: control group (CTL), dyslipidemic (DLP), who received a dyslipidemic diet and placebo solution (PBS), and the group with L. fermentum 296 (DLP + Lf296) with dyslipidemic diet and gavage supplementation with L. fermentum 296 (1.0 x 109 CFU / mL) daily for 4 weeks. At the end of the study, blood was collected for biochemical tests, oral glucose tolerance (OGT) and insulin (TTI) tests were performed, and finally the rats were submitted to surgery for insertion of cannulas into the femoral artery for posterior measurement of the basal blood pressure, obtaining heart rate (HR) records, spectral analysis of systolic blood pressure and pulse interval, baroreflex sensitivity, sympathetic-vagal balance and sympathetic vascular tone in each group. The rats were euthanized and the organs were collected for weighing. Finally, the faeces were collected and the Lactobacillus spp count was performed. The intervention with L. fermentum 296 was able to prevent the increase of total cholesterol levels (111.5 ± 10 vs. 161 ± 18.2 mg / dl), LDL (84.9 ± 10.7 vs. 142.6 ± 20.9 mg / dl), and triglycerides (52.5 ± 4.6 vs. 85 ± 8.3 mg / dl) (p <0.05) in dyslipidemic rats. The administration of L. fermentum 296 prevented increased systolic blood pressure (149.5 ± 3.3 vs. 162.5 ± 1.6 mmHg, p <0.05), and sympathetic cardiovascular tone (-50.8 ± 3.5 vs. -63.4 ± 3.0 mmHg, p < 0.05) in rats fed a dyslipidemic diet. The administration of L. fermentum 296 was not able to prevent insulin resistance (p> 0.05) and damage in cardiac baroreflex control (p> 0.05) caused by the dyslipidemic diet. These results indicate that L. fermentum 296 presents potential for use as a probiotic with the ability to modulate biochemical and cardiovascular parameters of interest for the treatment of cardiometabolic diseases. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-03-21 2019-04-18 2020-01-13T14:27:01Z 2020-01-13T14:27:01Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufpb.br/jspui/handle/123456789/16735 |
url |
https://repositorio.ufpb.br/jspui/handle/123456789/16735 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
Attribution-NoDerivs 3.0 Brazil http://creativecommons.org/licenses/by-nd/3.0/br/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution-NoDerivs 3.0 Brazil http://creativecommons.org/licenses/by-nd/3.0/br/ |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Universidade Federal da Paraíba Brasil Ciências da Nutrição Programa de Pós-Graduação em Ciências da Nutrição UFPB |
publisher.none.fl_str_mv |
Universidade Federal da Paraíba Brasil Ciências da Nutrição Programa de Pós-Graduação em Ciências da Nutrição UFPB |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UFPB instname:Universidade Federal da Paraíba (UFPB) instacron:UFPB |
instname_str |
Universidade Federal da Paraíba (UFPB) |
instacron_str |
UFPB |
institution |
UFPB |
reponame_str |
Biblioteca Digital de Teses e Dissertações da UFPB |
collection |
Biblioteca Digital de Teses e Dissertações da UFPB |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB) |
repository.mail.fl_str_mv |
diretoria@ufpb.br|| diretoria@ufpb.br |
_version_ |
1801842956572819456 |